MagForce AG : MagForce AG Publishes First Quarterly Shareholder Letter

    MagForce AG : MagForce AG Publishes First Quarterly Shareholder Letter

MagForce AG / MagForce AG Publishes First Quarterly Shareholder Letter . Ad
hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this
announcement.

Berlin, Germany, July 24, 2013 - MagForce AG (Frankfurt, Xetra: MF6), a
leading medical device company in the area of nanotechnology with a focus on
oncology, published today its first "Shareholder Letter".

Subsequently, such shareholder letters shall be published quarterly in order
to keep shareholders well informed about the ongoing developments and
progress.

The shareholder letter can be downloaded here:
http://www.magforce.de/en/presse-investoren/aktionaersbriefe.html

Key points are

  *Personal introduction of Dr. Ben Lipps, designated CEO and Chairman of the
    Management Board
  *Focus on recurrent Glioblastoma Multiform Cancer (GBM) and Prostate Cancer
  *Details to GBM post-marketing study
  *Search for strategic partners in Emerging Markets.

About MagForce AG
MagForce AG is a leading medical  device company in the field of  nanomedicine 
in oncology, listed in  the entry standard  (MF6). The Company's  proprietary, 
NanoTherm^® therapy, enables  the targeted treatment  of solid tumors  through 
the intratumoral  generation  of  heat  via  activation  of  superparamagnetic 
nanoparticles. NanoTherm^®, NanoPlan^®,  and NanoActivator(TM) are  components 
of the  therapy  and have  received  EU-wide regulatory  approval  as  medical 
devices for the treatment of brain tumors. MagForce, NanoTherm^®,  NanoPlan^®, 
and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For
more information, please visit www.magforce.com.

Full Resume Dr. Ben Lipps
Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management
Board of Fresenius Medical Care in May 1999. In December 2012 he stepped  down 
as Chairman  of the  Management  Board and  CEO.  During his  term,  Fresenius 
Medical Care's sales tripled from 3.8 to 12.8 billion dollars, and the  annual 
net profit grew 6 times to 1.1 billion dollars.
He was also Chief  Executive Officer of Fresenius  Medical Care North  America 
until  February  2004.  He  was  President,  Chief  Executive  Officer,  Chief 
Operating Officer and a  director of Fresenius USA  from October 1989  through 
February  2004,  and  served  in  various  capacities  with  Fresenius   USA's 
predecessor from 1985 through 1989.

He earned his master's and doctoral degrees at the Massachusetts Institute  of 
Technology in  chemical engineering.  Before joining  the Fresenius  Group  in 
1985,  Dr.  Lipps  held  several  research  management  positions  in  various 
companies, among them with DOW Chemical.

Disclaimer
This release may contain forward-looking statements and information which  may 
be  identified  by  formulations  using  terms  such  as  "expects",   "aims", 
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will".
Such forward-looking  statements are  based on  our current  expectations  and 
certain  assumptions,  which  may  be  subject  to  a  variety  of  risks  and 
uncertainties. The results actually achieved by MagForce AG may  substantially 
differ  from  these  forward-looking   statements.  MagForce  AG  assumes   no 
obligation to update these  forward-looking statements or  to correct them  in 
case of developments, which differ from those, anticipated.

Contact:
Anne Hennecke
MC Services AG

T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759

Email: anne.hennecke@mc-services.eu

MagForce_Press Release_July 24, 2013

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MagForce AG via Thomson Reuters ONE
HUG#1718378

--- End of Message ---

MagForce AG
Max-Dohrn-Str. 8 Berlin Germany

WKN: A0HGQF;ISIN: DE000A0HGQF5;
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
 
Press spacebar to pause and continue. Press esc to stop.